Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jan 31, 2023 7:40pm
130 Views
Post# 35258269

RE:Twitter - AGM date

RE:Twitter - AGM date With the AGM now announced for Feb.28th plus a PP that has no stated closing date it looks like we will not be hearing much for the next 4 weeks.  I may be wrong but I don't expect any updates until the AGM. At the AGM which is open to all shareholders, questions will be asked which will need to be answered.  Let's hope those answers include the expected submission date for Dermaprecise.

 Also the great unknown is what is Shiseido planning to do.  They don't need to do anything at this point. The may have decided to wait this out until a judgement which could be as late as the end of July.  On the other hand they may see the outcome is not looking good and make Replicel an offer.  The structure of that offer could come in a number of ways.  I think many shareholders are hoping for a buyout.  Another scenario which is not likely is Shiseido and Replicel decide to work together to bring RCH-01 to market. A third and even less likely scenario is Shiseido returns the contract and turns the data from their two Trials over to Replicel.
Anyways regardless of these musings we as usual continue to wait.  
<< Previous
Bullboard Posts
Next >>